These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38097548)

  • 21. The Potential of Targeting P53 and HSP90 Overcoming Acquired MAPKi-Resistant Melanoma.
    Hsieh CC; Shen CH
    Curr Treat Options Oncol; 2019 Feb; 20(3):22. PubMed ID: 30778775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
    Monteith JA; Mellert H; Sammons MA; Kuswanto LA; Sykes SM; Resnick-Silverman L; Manfredi JJ; Berger SL; McMahon SB
    Mol Oncol; 2016 Oct; 10(8):1207-20. PubMed ID: 27341992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
    Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM
    Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis.
    Matin RN; Chikh A; Chong SL; Mesher D; Graf M; Sanza' P; Senatore V; Scatolini M; Moretti F; Leigh IM; Proby CM; Costanzo A; Chiorino G; Cerio R; Harwood CA; Bergamaschi D
    J Exp Med; 2013 Mar; 210(3):581-603. PubMed ID: 23420876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
    Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
    J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs.
    Puca R; Nardinocchi L; Porru M; Simon AJ; Rechavi G; Leonetti C; Givol D; D'Orazi G
    Cell Cycle; 2011 May; 10(10):1679-89. PubMed ID: 21508668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment.
    Hoffman-Luca CG; Yang CY; Lu J; Ziazadeh D; McEachern D; Debussche L; Wang S
    PLoS One; 2015; 10(6):e0128807. PubMed ID: 26070072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutant p53 proteins bind DNA in a DNA structure-selective mode.
    Göhler T; Jäger S; Warnecke G; Yasuda H; Kim E; Deppert W
    Nucleic Acids Res; 2005; 33(3):1087-100. PubMed ID: 15722483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
    Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
    Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gain-of-function mutant p53 in cancer progression and therapy.
    Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
    J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autophagy induced by SAHA affects mutant P53 degradation and cancer cell survival.
    Foggetti G; Ottaggio L; Russo D; Mazzitelli C; Monti P; Degan P; Miele M; Fronza G; Menichini P
    Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30745455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.
    Jethwa A; Słabicki M; Hüllein J; Jentzsch M; Dalal V; Rabe S; Wagner L; Walther T; Klapper W; ; Bohnenberger H; Rettel M; Lu J; Smits AH; Stein F; Savitski MM; Huber W; Aylon Y; Oren M; Zenz T
    Blood; 2018 Jun; 131(25):2789-2802. PubMed ID: 29653964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status.
    Garufi A; Baldari S; Pettinari R; Gilardini Montani MS; D'Orazi V; Pistritto G; Crispini A; Giorno E; Toietta G; Marchetti F; Cirone M; D'Orazi G
    J Exp Clin Cancer Res; 2020 Jun; 39(1):122. PubMed ID: 32605658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Wild-type p53 in cancer cells: when a guardian turns into a blackguard.
    Kim E; Giese A; Deppert W
    Biochem Pharmacol; 2009 Jan; 77(1):11-20. PubMed ID: 18812169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
    Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
    Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reactivation of p53 as therapeutic intervention for malignant melanoma.
    Jochemsen AG
    Curr Opin Oncol; 2014 Jan; 26(1):114-9. PubMed ID: 24275854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gambogic acid counteracts mutant p53 stability by inducing autophagy.
    Foggetti G; Ottaggio L; Russo D; Monti P; Degan P; Fronza G; Menichini P
    Biochim Biophys Acta Mol Cell Res; 2017 Feb; 1864(2):382-392. PubMed ID: 27899303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.
    Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T
    J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction.
    Tran TQ; Lowman XH; Reid MA; Mendez-Dorantes C; Pan M; Yang Y; Kong M
    Oncogene; 2017 Apr; 36(14):1991-2001. PubMed ID: 27721412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
    Stiewe T; Haran TE
    Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.